MDXG MiMedx Group, Inc.
USHealthcareAs of 2026-07-10 16:00
Why MDXG matters now
MiMedx Group, Inc. (MDXG) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.11 with -0.72% on the session and $612.2M in market capitalization; recent performance reads 1-month +0.82% and YTD -45.79%.
The latest financial table shown here is Q1 2026, with revenue of $59.0M, net income of $-10.9M, and EPS of $-0.07. Investors can compare that operating picture with valuation signals such as P/E 11.81 and FCF yield 12.0%.
The latest indexable market news headline is "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $10.00; recent insider activity includes Olson Tiffany filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
11.81
PEG
0.81
P/B
2.24
P/S
1.40
EV/EBITDA
7.06
DCF Value
$3.82
FCF Yield
12.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
81.0%
Operating Margin
10.2%
Net Margin
7.9%
ROE
12.9%
ROA
9.9%
ROIC
10.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $59.0M | $-10.9M | $-0.07 |
| Q4 2025 | $118.1M | $15.2M | $0.10 |
| FY 2025 | $418.6M | $48.6M | $0.32 |
| Q3 2025 | $113.7M | $16.7M | $0.11 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$10.00
Target (Median)
$10.00
Target Range
$10.00 - $10.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.46
MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucial for manufacturing allografts that preserve the natural biological characteristics and essential regulatory proteins of the original tissue. This exclusive and patented processing technique incorporates both aseptic procedures and a final sterilization step, ensuring product safety and efficacy. Among its offerings is EpiFix, a semi-permeable membrane designed to act as a protective barrier, effectively treating persistent wounds such as diabetic foot ulcers, venous leg ulcers, and pressure sores. Another key product is AmnioFix, a protective, semi-permeable allograft made from dehydrated human amnion/chorion membrane, utilized to aid post-surgical recovery. EpiCord and AmnioCord, both derived from dehydrated human umbilical cord, function as allografts that foster a protective healing environment and are applied in both advanced wound care and surgical recovery contexts. AMNIOBURN is also a semi-permeable protective allograft specifically developed for managing partial and full-thickness burn injuries. Its flagship product, mdHACM, is a micronized, powdered version of AMNIOFIX. These products predominantly find use in healthcare sectors like wound management, burn treatment, surgical procedures, and non-operative sports medicine. Additionally, the company supplies allografts for dental uses to other manufacturers on an original equipment manufacturer (OEM) basis. Distribution of its products primarily occurs within the United States, facilitated by its own sales teams, independent agents, and various independent distributors. MiMedx Group, Inc.'s main office is located in Marietta, Georgia.